Also categorized in BoardNews:
Six Years Later, The Problem at HP is Still the Board
x hide permanently

Mylan Board Faces Challenge From Shareholder Advisory Firms


A major shareholder advisory firm is calling for investors to vote to unseat all of Mylan NV ’s incumbent board directors after they failed to stop “significant destruction in shareholder value,” high executive pay and missteps during a drug pricing controversy over its allergy shot EpiPen...

Mentions: Investors Epipen Mylan